The increasing use of complementary and alternative medicines (CAMs) has been associated with a rising incidence of CAM-induced drug-induced liver injury (DILI). The aim of this study was to examine the clinical features and outcomes among patients with acute liver failure (ALF) and acute liver injury (ALI) enrolled in the Acute Liver Failure Study Group database, comparing CAM-induced with prescription medicine (PM)-induced DILI.
INTRODUCTION
Idiosyncratic drug-induced liver injury (DILI) is a relatively rare event with an estimated incidence of 14-19 events per 100,000 individuals ( 1, 2 ) . It accounts for 13% of all cases of acute liver failure (ALF) in the United States, second only to acetaminopheninduced liver failure ( 3 ) . DILI manifests in a variety of clinical presentations and is associated with a 13-17% risk of unresolved or chronic injury at 6 months, a 2-4% transplantation rate, and a 6-8% mortality rate ( 4, 5 ) . For those who progress to ALF, transplant-free survival at 3 weeks is only 27.1% with an overall survival rate of 66.2% ( 6 ) . Hundreds of prescription medications (PMs) have been implicated as causing DILI, with antimicrobials
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being the most frequently implicated group ( 4, 6, 7 ) . Complementary and alternative medications (CAMs) including multivitamins, herbals, dietary supplements, bodybuilding agents, and weight loss supplements are the second most common category of agents responsible for DILI ( 5, 6 ) . A recent population-representative study found that CAM accounts for nearly one in fi ve of all cases of DILI ( 8 ) .
Although PM must undergo vigorous clinical trials evaluating medication safety and are subject to strict US Food and Drug Administration (FDA) regulation, CAMs, on the other hand, are subject to less stringent regulation. Th ese agents are regulated under the Dietary Supplement Health and Education Act of 1994 and the Final Rule for Current Good Manufacturing Practices for Dietary Supplements of 2007. Manufacturers are responsible for ensuring the safety of, labeling of, and purity of their products without any requirement to prove effi cacy ( 9 ) . CAM agents can be marketed at any concentration, as long as daily recommended values (if applicable) are on the label, and oft en have signifi cant product-to-product variability ( 10, 11 ) . Contaminants can be oft en found in dietary supplements with reports of DILI attributed to these medications (12) (13) (14) .
In recent years, the use of CAM has been rising as nearly half of the US population reports using at least one dietary supplement (15) (16) (17) . Th is increase has been associated with a corresponding rise in the incidence of DILI attributed to these agents from 7 to 20% between 2004 and 2012 ( 18 ) . Th is same study showed that CAM that was not body building supplements typically presented as severe hepatocellular injury and required transplantation more frequently when compared with PM (13 vs. 3%) ( 18 ) . Th e high liver transplantation rate from this study suggests that CAM-induced DILI may be more severe than PM-induced DILI.
Th e Acute Liver Failure Study Group (ALFSG) was established in 1997 to prospectively study patients with all causes of ALF, and expanded their registry in 2008 to include those with acute liver injury (ALI) to better understand the epidemiology of disease and to elucidate the pathogenesis, mechanism, and outcomes of liver injury. Th e purpose of this study was to better characterize CAM-induced liver injury using data from the US ALFSG, and compare this type of liver injury with that caused by PM.
METHODS

Study design
From 20 January 1998 to 1 April 2015, 2,626 subjects meeting entry criteria for ALF or ALI were prospectively enrolled at up to 32 academic liver transplant centers participating in the National Institutes of Health (NIH)-funded ALFSG (see Supplementary Methods online for complete listing). All patients with ALI were enrolled aft er September 2008, when the ALFSG began collecting these data. Written informed consent was obtained from patients with ALI or their next-of-kin for those with ALF. All centers complied with their local Institutional Review Boards' requirements and the Health Insurance Portability and Accountability Act (HIPAA).
Inclusion criteria
Patients were at least 18 years of age at the time of enrollment. All patients were hospitalized. ALF was defi ned as hepatic encephalopathy (altered mentation to any degree) and moderately severe coagulopathy (international normalized ratio (INR) ≥1.5) and acute onset of illness <26 weeks; whereas ALI was defi ned as acute hepatic illness of <26 weeks with INR ≥2.0, alanine aminotransferase (ALT)≥10× upper limit of normal, total bilirubin ≥3.0 mg/dl, and the absence of hepatic encephalopathy.
Th e principal investigator at each site was responsible for collecting a detailed history including demographic data, medical history, social history, and medication history but not limited to prescription drugs, over-the-counter medications, dietary supplements, herbal supplements, xenobiotics, CAM, and illicit substances. Relevant clinical, biochemical, serologic, imaging, and in some cases, histologic data were obtained to elucidate the etiology of liver injury. Th is included serological testing hepatitis A, B, C, and E, cytomegalovirus, Epstein-Barr virus, herpes simplex virus, and autoimmune hepatitis as well as the metabolic marker ceruloplasmin for Wilson's disease. Subjects with preexisting cirrhosis were excluded.
Causality assessment
Non-acetaminophen DILI was diagnosed if the patient was taking a drug or substance with a strong association with idiosyncratic DILI and if competing causes of ALF/ALI were excluded by rigorous evaluation of aforementioned diagnostic work-up. From 1998 to 2014, DILI was diagnosed by an experienced hepatologist at the local site and then each case was scrutinized and independently confi rmed as a case of DILI by the authors at the ALFSG central site. From 2014 to 2015, DILI was diagnosed according to DILIN guidelines, only including those cases determined to be defi nite (>95% probability), highly likely (75-95%), or probably (50-75%) ( 19 ) . Subjects deemed as possible or unlikely (probability <50%) were re-adjudicated as indeterminate. If multiple CAM agents were used concurrently, then this was adjudicated as a single case of DILI. Putative agents were then categorized aft er the causality indicated a >50% likelihood that the implicated agent was responsible for the case of ALI/ALF.
Characterizing DILI
DILI was characterized as hepatocellular, cholestatic, or mixed based on the "R" ratio as calculated by the ratio of serum alanine aminotransferase (ALT, as a multiple of its upper limit of normal) to the relative elevation of alkaline phosphatase (as a multiple of its upper limit of normal) on day 1 of enrollment ( 20 ) .
Categorizing patients and outcomes
Subjects with DILI were divided into two categories: CAM and PM. To avoid overlap, if PM was implicated in addition to CAM, these subjects were excluded from the study ( n =2). Data for both groups were compared including demographics, comorbidities, presenting symptoms, laboratory values, and calculated Model of End-Stage Liver Disease (MELD) score ( 21 ) . Lab values from the day of presentation were used for analysis. Outcomes at 21 days of enrollment were defi ned as transplant-free (spontaneous) survival, liver transplantation, or death. Patients who were transplanted but did not have known alive/dead status at day 21 were included in all other analysis for transplant-free survival but excluded from overall survival and mortality analysis. Subgroup analysis was performed on all of those with ALF, including those who progressed from ALI to ALF.
Statistical analysis
Descriptive statistics were used to present demographics, clinical characteristics, and outcomes. Continuous variables were reported as medians with interquartile ranges, due to the nonnormal distribution of the data. Diff erences in continuous variables between the CAM and PM groups, as well as CAM patients with a transplant-free survival and CAM patients, who received a transplant or died, were tested using the Wilcoxon rank-sum test. Diff erences in categorical variables between the groups were tested using a Chi-Square test or Fisher's exact test where applicable (expected cell sizes <5). A univariate logistic model was created as admission MELD predictive of transplant-free survival. A receiver operating characteristic curve was generated using the SAS Macro %ROCPLOT to fi nd an optimal cut point, by maximizing sensitivity and specifi city, of admission-MELD. All analysis was performed using SAS version 9.4 (SAS Institute, Cary, NC) and evaluated at the 0.05 signifi cance level.
RESULTS
Cases of liver injury
Between January 1998 and April 2015, the ALFSG enrolled 2,626 subjects with 253 (9.6%) adjudicated as DILI by methods as described above. Among those, two cases were excluded as both a CAM and a non-CAM agent (acetaminophen and montelukast) were identifi ed as potential causes of liver injury. Of the remaining 251 cases eligible for analysis, 210 (83.7%) were due to PM and 41 (16.3%) from CAM. Herbal supplements accounted for 63.4% of all CAM cases ( Table 1 ). Antimicrobials and antivirals were the most frequently implicated PM (48.6%) with isoniazid being the most common single agent ( n =27). Between 1998 and 7 July 2007, there were 154 cases of DILI, 17 of which were due to CAM (12.4%). From 8 July 2007-2015, of the 138 cases of DILI, 24 cases were attributed to CAM (21.1%), a statistically signifi cant increase in the percent of DILI cases due to CAM ( P =0.047).
Demographics
Patient demographics and comorbidities are shown in Table 2 . Th ere was no statistical signifi cant diff erence between the CAM and PM groups in regards to age, sex, BMI, or race. Among both groups, subjects were predominantly Caucasian, male, and overweight. Th ere was no diff erence in alcohol use within the preceding 6 months between groups. Subjects in the CAM group had signifi cantly less comorbidities than the PM subjects (median 1.0 vs. 2.0, P <0.001). As compared with the CAM group, comorbidities were more common among the PM in all categories including collagen/vascular, chronic liver, endocrine, psychiatric, neurologic, heart, renal, pulmonary, gastrointestinal, and immunodefi ciency disease, though only statistically signifi cant in regards to psychiatric and pulmonary disease.
Presenting symptoms
Th ere was no diff erence in presenting symptoms between the groups ( Table 2 ). Jaundice was the most common presenting symptom for both groups, being present in >90% of subjects. Th ere was also no diff erence in the onset of jaundice between CAM and PM groups. Malaise and nausea/vomiting were the next most common presenting symptoms.
Liver injury pattern
Th ere was no diff erence in the type of liver injury (hepato cellular, cholestatic, or mixed injury) between groups as determined by Herbalife cell activator Nitrofurantoin (10) Horny goat weed Anti-retroviral therapy (7) Kava kava Penicillin or cephalosporin (7) Ma huang Antifungal agent (6) Qat Doxycycline (5) Usnic acid Neurologic medications (20) Uva-ursi and buchu leaf Phenytoin (7) Valerian Cholesterol lowering agents (11) Multiple herbals (14) Statin (8) Dietary supplements (12) Antithyroid agents (8) C4 energy Propylthiouracil (7) Hydroxycut ( Hillman et al. 35 .6%, P <0.005) and lower 21-day transplant-free survival (17.4 vs. 34.4%, P =0.044) when comparing CAM with PM.
CAM subgroup analysis
Within the CAM group, those with 21-day transplant-free survival were more likely to have ALI than ALF when compared with those transplanted or dead ( Figure 1 ). Using this cutoff , four patients who died or were transplanted fell below this number and two patients who spontaneously survived were above this number, demonstrating a sensitivity and a specifi city in our population of 85.7 and 80%, respectively. No diff erences were observed in median ALT/AST, alkaline phosphatase, platelet count or bilirubin levels. Th ere was also no diff erence in liver injury pattern between these groups.
DISCUSSION
DILI secondary to CAM is becoming increasingly prevalent. ALF/ALI from CAM appears to be at least as severe in presentation as that observed in DILI secondary to conventional PM. As R score ( P =0.26) ( Table 3 ). Hepatocellular injury ( R score >5) was the most common injury pattern in both the CAM (80.0%) and PM (72.9%) groups. Th irty-two (78.1%) patients in the CAM group met criteria for ALF as compared with 186 (88.6%) in the PM though this was not statistically signifi cant ( P =0.16). On day 1 of enrollment, PM-induced DILI showed higher serum alkaline phosphatase levels compared with the CAM group (mean IU/l, 215.1 vs. 156.2, P =0.005); there were no diff erences between both cohorts in median ALT/AST (aspartate aminotransferase), INR, platelets, bilirubin, MELD score or coma grade.
CAM vs. PM outcomes
More patients with CAM-induced DILI were listed for liver transplantation vs. those with PM-induced DILI (65.9 vs. 47.1%, P =0.28) ( observed with other forms of liver failure, the MELD score was roughly concordant with outcomes for patients with ALF/ALI from CAM with respect to death or transplant. Th e higher rate of liver transplantation in patients with CAM-induced DILI is possibly explained by the fact that these patients had fewer comorbidities that might preclude transplantation. However, despite underlying genetic predispositions to DILI involving human leuko cyte antigen genotypes and genes involved in drug metabolism ( 25, 27 ) . Cell-based assays are being developed using immunerelated gene expression to help predict the risk of drug-specifi c DILI ( 28 ) . How this research will translate into clinical practice remains to be seen, but research eff orts focused on the mechanisms involved in CAM-induced DILI may ultimately produce in vitro testing that predicts the risk of DILI and thereby reduce or prevent CAM-induced liver injury. A clinical tool currently available is a recently published prognostic model that uses platelet count and total bilirubin to help predict patients with DILI at greatest risk for ALF ( 29 ) . Th e use of CAM is grossly under-reported. Nearly half of CAM users fail to report the use of these medications to their healthcare provider and oft en fail to disclose all CAM even when they do so ( 30, 31 ) . Physicians should have a high suspicion for CAM in otherwise healthy patients with unexplained liver enzyme abnormalities. Unfortunately, physician knowledge on the clinical use and safety profi le of CAM is poor, which discourages an open dialogue about the use of these therapies with patients ( 32 ) . Th is lack of knowledge also results in under-reporting of CAM-related adverse events. In fact, almost three in four physicians do not know how or where to report medication-related adverse events ( 33 ) . MedWatch ( http://www.fda.gov/Safety/MedWatch/HowToReport/ default.htm ) is one tool clinicians can use to report adverse events to the FDA ( 34 ) . More specifi c to DILI, www.LiverTox.nih.gov , an NIH-funded database with information on hundreds of compounds (including a few CAM) implicated in DILI can be used by physicians to research culprit substances when DILI is suspected ( 35 ) .
In conclusion, 16.3% of the idiosyncratic DILI associated with ALI/ALF in the ALFSG database are due to CAM. Th ese patients had signifi cantly higher transplantation rates compared with idiosyncratic DILI from PM, probably refl ecting a more severe clinical presentation and less comorbidities that precluded transplantation. Given the signifi cant potential for morbidity and mortality, patients presenting with suspected CAM-induced severe liver injury or liver failure should be considered for early referral and rapid evaluation at a liver transplant center. It is of concern that the proportion of idiosyncratic DILI cases secondary to CAM seem to be increasing in recent years, in all likelihood due to more prevalent use of CAM. We also propose that stricter reporting of CAM-induced DILI and better characterization of the mechanisms of hepatotoxicity from these compounds would help limit the serious outcomes associated with such over-thecounter products.
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Th e clinical signifi cance of higher alkaline phosphatase levels related to PM-induced DILI is unclear and was not described in a previous study ( 18 ) . All cases had abdominal imaging to exclude a biliary source of cholestasis. Cholestatic DILI has been well described. In fact, patients with jaundiced DILI have roughly a 10% short-term mortality ( 22 ) . However, there was no diff erence in bilirubin levels or diff erence in overall survival between groups in this study.
All of the patients in this study were hospitalized at tertiarycare centers with liver transplant services. Th is selective registry is only representative of the most severe cases of CAM-induced DILI: those that reach the threshold of ALI or ALF. It is likely that milder cases are under-recognized and under-reported. Although this study was confi ned to 21-day outcomes and did not examine long-term consequences of DILI, other studies have shown that the course can be protracted and some patients are left with sequelae of chronic liver disease ( 4 ). A major limitation of this study was the lack of latency data and medication dosage for most cases. When available, these data were collected but as the data were lacking for most cases, it was not included. Although most cases of DILI are idiosyncratic, including these data in future studies may help identify those agents that are truly hepatotoxic.
Exactly why CAM-induced DILI is more severe than PM is unclear. Th e mechanism of DILI is likely multifactorial and related to direct hepatoxicity, host factors, and drug-host interactions. Current research eff orts are underway to better understand the mechanism of DILI with a focus on the potential role of the immune system, mitochondrial injury, and impairment of bile salt excretion ( 23, 24 ) . Using histology and the emerging fi eld of pharmacogenetics, researchers are working on ways to better diag nose and predict DILI ( 25, 26 
Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ The use of complementary and alternative medicine (CAM)
is rising among the US population.
✓ CAM has been more frequently implicated in acute liver injury and failure.
WHAT IS NEW HERE
✓ Incidence of CAM-induced severe liver injury and acute liver failure is rising.
✓ Clinical features of CAM-induced injury as compared with prescription-induced injury are relatively uncharacterized.
✓ CAM-induced liver injury has higher transplantation rates and lower transplant-free survival than that observed with severe liver injury due to prescription medications.
